| Role for neuronal insulin resistance in neurodegenerative diseases M Schubert, D Gautam, D Surjo, K Ueki, S Baudler, D Schubert, T Kondo, ... Proceedings of the National Academy of Sciences 101 (9), 3100-3105, 2004 | 639 | 2004 |
| Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas NL Albert, M Weller, B Suchorska, N Galldiks, R Soffietti, MM Kim, ... Neuro-oncology 18 (9), 1199-1208, 2016 | 351 | 2016 |
| 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors AH Jacobs, A Thomas, LW Kracht, H Li, C Dittmar, G Garlip, N Galldiks, ... Journal of Nuclear Medicine 46 (12), 1948-1958, 2005 | 281 | 2005 |
| Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice MT Heneka, M Ramanathan, AH Jacobs, L Dumitrescu-Ozimek, ... Journal of Neuroscience 26 (5), 1343-1354, 2006 | 256 | 2006 |
| Advances in neuro-oncology imaging KJ Langen, N Galldiks, E Hattingen, NJ Shah Nature Reviews Neurology 13 (5), 279-289, 2017 | 162 | 2017 |
| Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18 F] fluoroethyl)-L-tyrosine PET N Galldiks, V Dunkl, G Stoffels, M Hutterer, M Rapp, M Sabel, ... European journal of nuclear medicine and molecular imaging 42 (5), 685-695, 2015 | 161 | 2015 |
| Role of O-(2-18F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis N Galldiks, G Stoffels, CP Filss, MD Piroth, M Sabel, MI Ruge, H Herzog, ... Journal of Nuclear Medicine 53 (9), 1367-1374, 2012 | 153 | 2012 |
| Response assessment of bevacizumab in patients with recurrent malignant glioma using [18 F] Fluoroethyl-L-tyrosine PET in comparison to MRI N Galldiks, M Rapp, G Stoffels, GR Fink, NJ Shah, HH Coenen, M Sabel, ... European journal of nuclear medicine and molecular imaging 40 (1), 22-33, 2013 | 150 | 2013 |
| Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma M Rapp, A Heinzel, N Galldiks, G Stoffels, J Felsberg, C Ewelt, M Sabel, ... Journal of nuclear medicine 54 (2), 229-235, 2013 | 142 | 2013 |
| Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a … U Herrlinger, T Tzaridis, F Mack, JP Steinbach, U Schlegel, M Sabel, ... The lancet 393 (10172), 678-688, 2019 | 141 | 2019 |
| Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI N Galldiks, KJ Langen, R Holy, M Pinkawa, G Stoffels, KW Nolte, ... Journal of Nuclear Medicine 53 (7), 1048-1057, 2012 | 141 | 2012 |
| The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma N Galldiks, G Stoffels, C Filss, M Rapp, T Blau, C Tscherpel, G Ceccon, ... Neuro-oncology 17 (9), 1293-1300, 2015 | 128 | 2015 |
| Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide W Wick, P Roth, C Hartmann, P Hau, M Nakamura, F Stockhammer, ... Neuro-oncology 18 (11), 1529-1537, 2016 | 123 | 2016 |
| Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version … I Law, NL Albert, J Arbizu, R Boellaard, A Drzezga, N Galldiks, ... European journal of nuclear medicine and molecular imaging 46 (3), 540-557, 2019 | 120 | 2019 |
| Use of 11 C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas N Galldiks, LW Kracht, L Burghaus, A Thomas, AH Jacobs, WD Heiss, ... European journal of nuclear medicine and molecular imaging 33 (5), 516-524, 2006 | 116 | 2006 |
| PET-based molecular imaging in neuroscience AH Jacobs, H Li, A Winkeler, R Hilker, C Knoess, A Rueger, N Galldiks, ... European journal of nuclear medicine and molecular imaging 30 (7), 1051-1065, 2003 | 116 | 2003 |
| From the clinician's point of view-What is the status quo of positron emission tomography in patients with brain tumors? N Galldiks, KJ Langen, WB Pope Neuro-oncology 17 (11), 1434-1444, 2015 | 110 | 2015 |
| Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma N Galldiks, G Stoffels, MI Ruge, M Rapp, M Sabel, G Reifenberger, ... Journal of Nuclear Medicine 54 (12), 2046-2054, 2013 | 99 | 2013 |
| Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors CP Filss, N Galldiks, G Stoffels, M Sabel, HJ Wittsack, B Turowski, ... Journal of nuclear medicine 55 (4), 540-545, 2014 | 97 | 2014 |
| Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas MD Piroth, M Pinkawa, R Holy, J Klotz, S Schaar, G Stoffels, N Galldiks, ... Strahlentherapie und Onkologie 188 (4), 334-339, 2012 | 97 | 2012 |
Karl-Josef LangenDirección de correo verificada de fz-juelich.de
